#1 Clinical Trials Search in Europe

Clofazimine

Clofazimine, a drug traditionally used to treat leprosy, is now being investigated for its potential in treating various mycobacterial infections and even COVID-19. This article explores recent clinical trials that are evaluating the efficacy and safety of clofazimine in different formulations and combinations for conditions such as nontuberculous mycobacterial (NTM) infections, Mycobacterium avium complex (MAC) lung disease, and SARS-CoV-2 infection.

Table of Contents

What is Clofazimine?

Clofazimine, also known by its brand name Lamprene, is an antibiotic medication that has been used for decades to treat various bacterial infections[1]. It was initially approved by the U.S. Food and Drug Administration (FDA) in 1986 for the treatment of leprosy, a chronic infectious disease caused by Mycobacterium leprae bacteria[2]. However, over the years, researchers and healthcare professionals have discovered its potential in treating other conditions, particularly those caused by different types of mycobacteria.

Conditions Treated with Clofazimine

Clofazimine is used to treat several conditions, including:

  • Leprosy: This is the primary condition for which clofazimine was initially approved[3].
  • Nontuberculous Mycobacterial (NTM) Infections: These are lung infections caused by bacteria similar to those that cause tuberculosis, but are typically less severe. Clofazimine has shown promise in treating NTM infections, particularly those caused by Mycobacterium avium complex (MAC) and Mycobacterium abscessus[1][2].
  • Multidrug-Resistant Tuberculosis (MDR-TB): Clofazimine is being studied as part of combination therapies for treating tuberculosis that is resistant to standard antibiotics[4].
  • Cryptosporidiosis: This is a parasitic infection that causes diarrhea. Clofazimine is being investigated for its potential in treating this condition, particularly in people with HIV[5].

How Clofazimine Works

Clofazimine is believed to work by interfering with the growth and reproduction of bacteria. It is thought to act in two main ways:

  1. It may inhibit the formation of certain structures within the DNA of bacteria, which slows down their growth[4].
  2. It has anti-inflammatory properties, which can help reduce the body’s immune response to the infection. This is particularly useful in conditions like leprosy, where much of the damage is caused by the body’s reaction to the bacteria[3].

How Clofazimine is Administered

Clofazimine is typically administered orally in the form of capsules. The dosage and duration of treatment can vary depending on the condition being treated:

  • For NTM infections, a common dosage is 100 mg once daily, taken with meals[2].
  • In some clinical trials, higher doses of 200-300 mg daily are being studied for short periods, followed by lower maintenance doses[1].
  • Clofazimine is usually part of a combination therapy, meaning it’s taken along with other antibiotics to increase effectiveness and reduce the risk of drug resistance[4].

It’s important to note that clofazimine can accumulate in the body’s fatty tissues, resulting in a long elimination half-life of about 30 days. This means it takes several months to reach steady-state concentrations in the body[1].

Current Clinical Trials

Several clinical trials are currently underway to explore new uses and formulations of clofazimine:

  • A study is investigating the use of a loading dose regimen to achieve effective concentrations more quickly in patients with NTM infections[1].
  • Another trial is examining an inhaled form of clofazimine for treating NTM lung infections, which could potentially deliver the drug more directly to the site of infection[6].
  • Researchers are also studying clofazimine as part of new combination therapies for multidrug-resistant tuberculosis[4].
  • A trial is exploring the potential of clofazimine in treating cryptosporidiosis in HIV-positive patients[5].

Potential Side Effects

Like all medications, clofazimine can cause side effects. Some of the known side effects include:

  • Skin discoloration: Clofazimine can cause a pink to brownish-black discoloration of the skin, which is usually reversible but may take months to years to fade after stopping the medication[5].
  • Gastrointestinal issues: Some patients may experience abdominal pain, nausea, or diarrhea[5].
  • QT prolongation: This is a heart rhythm condition that can potentially lead to serious complications. Patients taking clofazimine are often monitored with electrocardiograms (ECGs)[4].
  • Liver toxicity: In some cases, clofazimine may affect liver function[5].

Important Considerations

When considering or using clofazimine, patients should keep in mind:

  • Clofazimine is typically used as part of a combination therapy, not as a standalone treatment[4].
  • The medication may not be readily available in all pharmacies and might require special ordering or access through specific programs[2].
  • Long-term use of clofazimine requires careful monitoring by healthcare professionals to manage potential side effects and ensure effectiveness[5].
  • Patients should inform their healthcare provider about all other medications they are taking, as clofazimine can interact with other drugs[4].
Condition Clofazimine Formulation Key Outcomes Measured Notable Findings/Objectives
Nontuberculous Mycobacterial (NTM) Disease Oral capsules (loading dose) Pharmacokinetics, safety, tolerability Exploring optimal dosing with loading dose regimen
MAC Lung Disease Inhalation Suspension Sputum culture conversion, quality of life Investigating efficacy when added to guideline-based therapy
Cryptosporidiosis in HIV+ patients Oral capsules Reduction in Cryptosporidium shedding, pharmacokinetics Assessing efficacy and safety in immunocompromised patients
Leprosy (ENL reactions) Oral capsules Incidence and severity of ENL reactions Evaluating extended use after completion of standard therapy
COVID-19 Oral capsules (with Interferon Beta-1b) Alleviation of symptoms, viral load reduction Exploring potential antiviral effects in combination therapy

FAQ

  • What is clofazimine and what is it traditionally used for? Clofazimine is an antibiotic drug that has been traditionally approved for the treatment of leprosy (Mycobacterium leprae infections). It has been used for decades and is known for its effectiveness against mycobacterial infections.
  • What new conditions are being studied for clofazimine treatment? Recent clinical trials are exploring the use of clofazimine for nontuberculous mycobacterial (NTM) infections, Mycobacterium avium complex (MAC) lung disease, cryptosporidiosis in HIV-positive patients, and even as a potential treatment for COVID-19.
  • How is clofazimine being administered in these new studies? The administration of clofazimine varies depending on the study. Some trials are using oral capsules, while others are investigating new formulations such as Clofazimine Inhalation Suspension for direct delivery to the lungs in cases of pulmonary infections.
  • What are some potential benefits of using clofazimine for NTM infections? Clofazimine has shown promise in treating NTM infections, particularly in cases where patients are intolerant to first-line drugs or have drug-resistant infections. It may help improve symptoms, reduce bacterial load, and potentially lead to better treatment outcomes when combined with other antibiotics.
  • Are there any notable side effects of clofazimine? Common side effects of clofazimine can include skin discoloration, gastrointestinal issues, and in some cases, changes in heart rhythm (QT prolongation). The ongoing clinical trials are closely monitoring these and other potential adverse events to ensure patient safety.

Ongoing Clinical Trials on Clofazimine

  • Study on the Effectiveness of Clofazimine and Drug Combination for Treating Mycobacterium abscessus Lung Disease in Adult Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of bedaquiline, pretomanid, linezolid and moxifloxacin combination treatment for patients with multidrug-resistant tuberculosis in France

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

Glossary

  • Nontuberculous Mycobacterial (NTM) Infections: Infections caused by mycobacteria other than those that cause tuberculosis and leprosy. These bacteria are commonly found in the environment and can cause lung, skin, or other infections, especially in people with weakened immune systems.
  • Mycobacterium Avium Complex (MAC): A group of bacteria that can cause lung infections similar to tuberculosis. MAC infections are a type of NTM infection and can be particularly challenging to treat, especially in people with compromised immune systems.
  • Erythema Nodosum Leprosum (ENL): A complication of leprosy characterized by painful skin nodules, fever, and other inflammatory symptoms. It's an immune reaction that can occur during or after treatment for leprosy.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. Understanding a drug's pharmacokinetics is crucial for determining the right dosage and administration schedule.
  • Sputum Culture Conversion: A measure of treatment effectiveness in mycobacterial infections where a patient's sputum (mucus coughed up from the lungs) changes from testing positive for the bacteria to testing negative, usually over a series of tests.
  • Quality of Life-Bronchiectasis Respiratory Symptoms Score (QoL-B RSS): A questionnaire used to assess the quality of life in patients with bronchiectasis, focusing specifically on respiratory symptoms. It's often used as an outcome measure in clinical trials for lung diseases.
  • Guideline-Based Therapy (GBT): The standard treatment approach recommended by medical guidelines for a particular condition. In the context of NTM infections, this typically involves a combination of antibiotics.
  • Cryptosporidiosis: An intestinal infection caused by the parasite Cryptosporidium. It can cause severe diarrhea, especially in people with weakened immune systems, such as those with HIV/AIDS.
  • Interferon Beta-1b: A type of protein naturally produced by the body that helps fight viral infections. In medical treatments, it's used as a drug for conditions like multiple sclerosis and is being studied for potential use against viral infections like COVID-19.

References

  1. https://clinicaltrials.gov/study/NCT05294146
  2. https://clinicaltrials.gov/study/NCT04334070
  3. https://clinicaltrials.gov/study/NCT01290744
  4. https://clinicaltrials.gov/study/NCT03828201
  5. https://clinicaltrials.gov/study/NCT03341767
  6. https://clinicaltrials.gov/study/NCT06418711